How the five judges who control half of all ANDA litigation are reshaping patent strategy, generic timelines, and drug revenue […]

Between 2025 and 2030, roughly $400 billion in annual pharmaceutical revenue becomes legally contestable. That figure is not a projection

The global generic drug market is not growing uniformly. It is concentrating. Between 2025 and 2030, branded drugs accounting for

Why a 20-Year Patent Rarely Means 20 Years of Revenue The statutory term creates a false ceiling. The effective commercial

For pharma IP teams, portfolio managers, R&D leads, and institutional investors assessing Russia exposure in 2025-2030. The Rouble Economy: Why

The “patent death squad” label has haunted PTAB since 2012. The actual data tells a different story — one where

Combination drugs — pairing a biologic with a small molecule — are among the most commercially valuable assets in pharma.

The global generic drug market will cross $700 billion by 2032. Most of that growth will not come from the

Generic drugs fill 90% of U.S. prescriptions and capture 18% of revenue. That gap is the whole game. The companies